---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-032536"
form_type: "8-K"
ticker: "PAVM"
cik: "0001624326"
company_name: "PAVmed Inc."
filed_at: "2022-11-15T23:59:59+00:00"
generated_at: "2026-06-21T18:33:00.604433+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PAVmed Q3 net loss $26.2M ($0.29/sh); EsoGuard volumes up 28% qoq to 1,088

## Summary
- GAAP net loss of $26.2M ($0.29 per share); non-GAAP adjusted loss of $13.8M ($0.15 per share).
- EsoGuard test volumes of 1,088 in Q3 2022, up 28% sequentially and 436% YoY.
- Cash and equivalents $56.8M at Sep 30, 2022, down from $77.3M at Dec 31, 2021.
- Issued $11.25M face value Senior Secured Convertible Note in Sep 2022; proceeds $10.2M.
- Veris Cancer Care Platform on track for commercial launch by end 2022; Lucid sales team targeting 58 professionals early 2023.

## SEC filing metadata
- accession: 0001493152-22-032536
- form_type: 8-K
- ticker: PAVM
- cik: 0001624326
- company_name: PAVmed Inc.
- filed_at: 2022-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1624326/000149315222032536/0001493152-22-032536-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1624326/000149315222032536/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-032536
- JSON: https://secwatch.observer/filing/0001493152-22-032536.json
- Plain text: https://secwatch.observer/filing/0001493152-22-032536.txt

## Key facts
- Earnings Releases
  PAVmed Inc. reported the three months ended September 30, 2022 results: revenue $0.1 million, net income approximately $26.2 million, EPS $(0.29) per common share.
  - Period: the three months ended September 30, 2022
  - Revenue: $0.1 million
  - Net income: approximately $26.2 million
  - EPS: $(0.29) per common share
  - Result: reported results
  source text: For the three months ended September 30, 2022, EsoGuard related revenues were $0.1 million. Operating expenses were approximately $23.4 million, which include stock-based compensation expenses of $4.8 million. GAAP net loss attributable to common stockholders was approximately $26.2 million, or $(0.29) per common share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1624326/000149315222032536/0001493152-22-032536-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.